Table 2 Crude and adjusted odds ratios for rifampicin resistance by sex, age, HIV status, history of previous treatment, region, and year of Xpert MTB/RIF assay administration. Total Mtb positive n = 147,327
Demographic and clinical characteristics | Rif-Resistant | Crude | Adjusted | |||
|---|---|---|---|---|---|---|
n | % | Odds ratio | 95% CI | Odds ratio | 95% CI | |
Sex | ||||||
Male | 9604 | 9.3 | reference | reference | ||
Female | 5056 | 11.4 | 1.25 | 1.21, 1.30 | 1.22 | 1.17, 1.26 |
Age | ||||||
> 30 years | 9881 | 8.9 | reference | reference | ||
< 31 years | 4779 | 13.1 | 1.54 | 1.49, 1.60 | 1.63 | 1.57, 1.70 |
HIV status | ||||||
Negative | 6720 | 9.1 | reference | reference | ||
Unknown | 6748 | 11.4 | 1.30 | 1.25, 1.34 | 1.01 | 0.97, 1.04 |
Positive | 1192 | 8.6 | 0.94 | 0.88, 1.01 | 0.87 | 0.82, 0.93 |
Previous treatment | ||||||
None | 7766 | 7.3 | reference | reference | ||
Unknown | 375 | 9.0 | 1.26 | 1.13, 1.40 | 1.31 | 1.18, 1.47 |
Yes | 6519 | 17.8 | 2.76 | 2.66, 2.86 | 2.85 | 2.75, 2.96 |
Selected Region | ||||||
Other regions | 6660 | 7.5 | reference | reference | ||
Yangon | 8000 | 13.7 | 2.0 | 1.89, 2.02 | 1.92 | 1.85, 1.99 |
Year of Test | ||||||
2015 | 2913 | 17.0 | reference | reference | ||
2016 | 3529 | 12.2 | 0.68 | 0.64, 0.72 | 0.79 | 0.75, 0.83 |
2017 | 4034 | 8.8 | 0.47 | 0.45, 0.50 | 0.65 | 0.62, 0.70 |
2018 | 4174 | 7.5 | 0.40 | 0.38, 0.42 | 0.58 | 0.55, 0.61 |